What is the 13F Pro Quality Score for ZVRA?

13F Pro ranks ZEVRA THERAPEUTICS, INC. (ZVRA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ZVRA's current score at https://13fpro.ai/research/ZVRA (free sign-up required for the full ranking).

Which hedge funds own the most ZVRA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ZVRA include BlackRock,, Woodline Partners, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ZVRA as soon as new 13F filings post.

Where does 13F Pro source ZVRA data?

All ZEVRA THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. ZEVRA THERAPEUTICS, INC. files with the SEC under CIK 1434647. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ZVRA in?

ZEVRA THERAPEUTICS, INC. (ZVRA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ZVRA research updated on 13F Pro?

ZVRA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ZEVRA THERAPEUTICS, INC.(ZVRA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1434647 ZVRA stock profile & AI dashboard →

13F Pro Quality Score

65.6/100

Rank #566 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

96.5/100

Profitability

96.5/100

Balance Sheet

99.2/100

Earnings Quality

30.0/100

Free Cash Flow

29.6/100

Institutional Flow

53.5/100

Revenue Scale

18.4/100

Dilution Risk

15.0/100

ZVRA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ZEVRA THERAPEUTICS, INC. (ZVRA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZVRA at 65.6/100 on a 32-signal composite quality model, placing it at rank #566 of 2,879 stocks — the top 25% of the AI-ranked universe. ZVRA scores in the top quartile across balance sheet strength (99.2), revenue growth (96.5), profitability (96.5). Areas of concern include revenue scale (18.4) and free cash flow (29.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ZEVRA THERAPEUTICS, INC. reports quarterly revenue of $36.2M, net income of $37.9M, free cash flow of $6.1M. Top institutional holders of ZVRA by reported 13-F value include BlackRock,, Woodline Partners, FMR, based on the most recent SEC filings. ZVRA trades on the Nasdaq exchange and files with the SEC under CIK 1434647. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZVRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ZEVRA THERAPEUTICS, INC. directly from SEC EDGAR. ZEVRA THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 7 and 66 since 2023, currently 65.6 — an improving long-term trajectory across 26 quarterly and live scoring snapshots.

✦

Fun facts about ZEVRA THERAPEUTICS, INC.

Quirks, history, and lore behind ZVRA — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company listed on Nasdaq, headquartered in North Carolina, focused on developing and commercializing treatments for rare diseases.
2
The Numbers
Revenue is in the tens of millions of dollars annually — tiny by pharma standards — with a market cap that hovers in the low hundreds of millions, the classic micro/small-cap biotech profile.
3
The History
The company rebranded and refocused in the early 2020s, pivoting squarely toward rare neurological and metabolic disorders after years of operating under a different identity.
4
The Secret
Its lead commercial product targets Niemann-Pick disease type C — a devastating, ultra-rare lysosomal storage disorder — giving it a near-monopoly niche in a tragically underserved patient population.
5
The Lore
The FDA granted its flagship drug Breakthrough Therapy designation, and the drug received accelerated approval — rare disease companies live and die by these regulatory milestones.
6
The Giveaway
Its commercial product MIPLYFFA (arimoclomol) for Niemann-Pick disease type C and its pipeline drug KP1077 for idiopathic hypersomnia are the twin pillars of this company that literally put "Zevra" in its name to signal a new chapter.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$36.2M

Net Income

Q1 2026

$37.9M

Free Cash Flow

Q1 2026

$6.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+350.9% YoY

$106.5MFY 2025

FY22 $10.2MFY23 $27.5MFY24 $23.6MFY25 $106.5M

Net Income

+178.9% YoY

$83.2MFY 2025

FY22 $-26.8MFY23 $-46.0MFY24 $-105.5MFY25 $83.2M

Operating Income

+27.7% YoY

$-62.9MFY 2025

FY22 $-42.6MFY23 $-49.6MFY24 $-87.0MFY25 $-62.9M

EPS (Diluted)

+159.2% YoY

$1.35FY 2025

FY22 —FY23 —FY24 $-2.28FY25 $1.35

Total Assets

+59.8% YoY

$284.7MFY 2025

FY22 $115.3MFY23 $172.3MFY24 $178.1MFY25 $284.7M

Total Debt

+4.1% YoY

$61.9MFY 2025

FY22 —FY23 $5.1MFY24 $59.5MFY25 $61.9M

Op. Cash Flow

+97.7% YoY

$-1.6MFY 2025

FY22 $-18.7MFY23 $-33.5MFY24 $-69.7MFY25 $-1.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$106.5M +350.9%	$23.6M -14.0%	$27.5M +170.3%	$10.2M -64.5%	$28.6M +123.1%	$12.8M
Net Income	$83.2M +178.9%	$-105.5M -129.1%	$-46.0M -72.0%	$-26.8M -212.9%	$-8.6M +65.1%	$-24.5M
Operating Income	$-62.9M +27.7%	$-87.0M -75.4%	$-49.6M -16.5%	$-42.6M -650.7%	$7.7M +138.0%	$-20.3M
EPS (Diluted)	$1.35 +159.2%	$-2.28	—	—	$-2.11	—
Total Assets	$284.7M +59.8%	$178.1M +3.4%	$172.3M +49.4%	$115.3M -13.2%	$132.9M +1165.3%	$10.5M
Total Debt	$61.9M +4.1%	$59.5M +1074.6%	$5.1M	—	—	$77.3M
Operating Cash Flow	$-1.6M +97.7%	$-69.7M -107.7%	$-33.5M -79.2%	$-18.7M -279.3%	$10.4M +144.0%	$-23.7M

AI Insight: ZVRA Financial Trends

ZVRA pivoted to profitability in Q1 2026 with $36M revenue and $52M operating income, while eliminating all debt.

• Revenue grew 800% from $4M (Q2 2024) to $36M (Q1 2026); operating margin swung from -600% to +144% in latest quarter.

• Net income turned positive: $38M in Q1 2026 vs. cumulative losses exceeding $90M across Q2–Q4 2024.

• Total debt eliminated to $0M in Q1 2026 from $58–62M baseline; equity surged to $206M from $32M in Q2 2024.

⚠ Operating cash flow remains modest at $6M (Q1 2026) despite $52M operating income; verify working capital timing.

⚠ Q2 2025 net income spike ($75M) followed by reversion to near-break-even in Q3; confirm sustainability of Q4–Q1 gains.

AI Insight: ZVRA Ratio Trends

ZVRA swung from deep losses in early 2025 to blockbuster profitability by Q1 2026, with operating margin surging to 144% and debt eliminated.

• Operating margin expanded from -26.3% in Q1 2025 to 144.0% in Q1 2026; net profit margin climbed to 104.6%.

• ROA improved from -7.2% in Q1 2025 to 54.4% in Q1 2026; ROE reached 73.6% in latest quarter.

• Debt-to-equity ratio fell from 1.46 in Q1 2025 to 0.00 in Q1 2026, indicating complete debt elimination.

⚠ Exceptional Q1 2026 metrics appear anomalously strong relative to TTM trend; verify sustainability of 144% OpMargin.

Get alerted when ZVRA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ZEVRA THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ZVRA

BlackRock, Inc.
$41.5M4,456,476 sh
Woodline Partners LP
$32.2M3,450,943 sh
FMR LLC
$29.9M3,211,877 sh
Nantahala Capital Management, LLC
$23.5M2,521,936 sh
VANGUARD CAPITAL MANAGEMENT LLC
$23.0M2,469,328 sh
Caption Management, LLC
$18.7M2,002,800 sh
STATE STREET CORP
$14.6M1,561,569 sh
GEODE CAPITAL MANAGEMENT, LLC
$12.8M1,371,857 sh
AIGH Capital Management LLC
$11.2M1,200,000 sh
MORGAN STANLEY
$11.1M1,192,262 sh

Fund	Value	Shares
BlackRock, Inc.	$41.5M	4,456,476
Woodline Partners LP	$32.2M	3,450,943
FMR LLC	$29.9M	3,211,877
Nantahala Capital Management, LLC	$23.5M	2,521,936
VANGUARD CAPITAL MANAGEMENT LLC	$23.0M	2,469,328
Caption Management, LLC	$18.7M	2,002,800
STATE STREET CORP	$14.6M	1,561,569
GEODE CAPITAL MANAGEMENT, LLC	$12.8M	1,371,857
AIGH Capital Management LLC	$11.2M	1,200,000
MORGAN STANLEY	$11.1M	1,192,262

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ZVRA on your watchlist

Track score changes the day ZEVRA THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ZVRA a good stock to buy?

13F Pro's AI-powered analysis of ZEVRA THERAPEUTICS, INC. (ZVRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZVRA are available on the ZVRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ZVRA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZVRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ZEVRA THERAPEUTICS, INC.'s investment landscape.